Skip to content

Belumosudil

ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS

Also known as: belumosudil mesylate, KD025, rezurock, SLx-2119

OnpFDA approvedOrphan designationATC L04AA48

Data last refreshed: (DrugCentral release 2024-11-01)

Key facts

Belumosudil is an onp drug catalogued in DrugCentral. It was first approved by the FDA in 2021. DrugCentral lists 2 molecular targets, including ROCK1 and ROCK2. Recorded indications include Chronic graft-versus-host disease (chronic GVHD).

  • Approval status: onp (first approved 2021 by the FDA).
  • Molecular targets: ROCK1 and ROCK2 (2 listed in DrugCentral).
  • Indications: Chronic graft-versus-host disease (chronic GVHD).
  • ATC code: L04AA48 (Selective immunosuppressants).
  • Molecular formula: C26H24N6O2; molecular weight 452.52 g/mol.

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (1)

  • Chronic graft-versus-host disease (chronic GVHD)

Mechanism & targets

Molecular targets (2)

TargetGeneActionActivity
Rho-associated protein kinase 1ROCK1inhibitorIC50 5.52
Rho-associated protein kinase 2ROCK2inhibitorIC50 5.52

Regulatory approvals (1)

DateAgencyMarketed asApplicantOrphan
2021-07-16FDA—KADMON PHARMA LLCYes

ATC classification

ATC codeTherapeutic hierarchy
L04AA48ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › IMMUNOSUPPRESSANTS › IMMUNOSUPPRESSANTS › Selective immunosuppressants

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA termLLR
Inappropriate schedule of product administration732.6
Product use in unapproved indication553.2
Hospitalisation128.2
Chronic graft versus host disease90.3
Alveolar proteinosis84.5
Chronic graft versus host disease in skin66.7
Disease progression63.5
Chronic graft versus host disease in eye56.5
Chronic graft versus host disease in intestine54.5
Chronic graft versus host disease oral53.7
Graft versus host disease52.4
Graft versus host disease in lung46.6

Chemical structure

Full physicochemical, ADMET and 3D-structure analysis of Belumosudil is on its molecule page.

Molecular formulaC26H24N6O2
Molecular weight452.52 g/mol
CAS number911417-87-3
InChIKeyGKHIVNAUVKXIIY-UHFFFAOYSA-N
PubChem CID11950170
CC(C)NC(=O)COC1=CC=CC(=C1)C2=NC3=CC=CC=C3C(=N2)NC4=CC5=C(C=C4)NN=C5

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Belumosudil used for?

DrugCentral lists the following indications for Belumosudil: Chronic graft-versus-host disease (chronic GVHD).

How does Belumosudil work?

Its molecular targets in DrugCentral include ROCK1 (inhibitor) and ROCK2 (inhibitor).

When was Belumosudil first approved?

Belumosudil was first approved by the FDA in 2021.

What is the chemical formula of Belumosudil?

Belumosudil has the molecular formula C26H24N6O2 and a molecular weight of 452.52 g/mol.

Browse: all drugs starting with B · drug guides by category · protein targets A–Z.

Sources

How this page is built: methodology · editorial policy & corrections.

For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.

Quick facts

StatusONP
First approval2021-07-16
AgencyFDA
Targets2
Indications1
FormulaC26H24N6O2
DrugCentral ID5467
Interactive profile